Contribution of a world-class regulatory system to the future of the pharmaceutical industry in Ireland

1,112 views

Published on

Delivered by Pat O'Mahony, Chief Executive, Irish Medicines Board at the IPHA Annual Meeting 2010.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,112
On SlideShare
0
From Embeds
0
Number of Embeds
171
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Contribution of a world-class regulatory system to the future of the pharmaceutical industry in Ireland

  1. 1. Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines Board Chairman, European Medicines Agency
  2. 2. Slide 2 REGULATORY ENVIRONMENT IMB operates within the European Medicines Regulatory System and Network European Medicines Agency (EMA) 47 National Competent Authorities (NCAs) And then as part of the Global Network
  3. 3. Slide 3 EUROPEAN MEDICINES AGENCY (EMA) Decentralised body of the European Union Its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use Scientific evaluation Pharmacovigilance Scientific advice Network of over 4,500 European experts Referrals and arbitration
  4. 4. Slide 4 THE EMA ROAD MAP TO 2015  Is a continuation of the Road Map to 2010 project, building on current achievements, but also taking due account of the Agency’s business drivers.  Provides the Agency’s vision on how it should further develop itself as a public health Agency.  Encompasses the Agency’s longer term strategy for both human and veterinary medicines.  Recognises the important contribution by the NCAs through the provision of high-quality scientific resources for the evaluation and supervision of medicinal products.  Will be complemented with a document “From Vision to Reality” and a multi-annual work programme.
  5. 5. Slide 5 47 NCAs AND HEADS OF MEDICINES AGENCIES (HMA) HMA Strategic Plan 2011-2015 Public and Animal Health Regulation Communication Network • Promoting & protecting public health • Pharmacovigilance • Quality and inspections Additional areas of competence, including devices • Availability of medicines Environmental analysis • Proportionate regulation • Consistency of implementation / harmonisation, e.g. Clinical trials work • Veterinary regulation • Interactions with industry/ stakeholders • Website presence • Resources • IT • Training
  6. 6. Slide 6 HEADS OF MEDICINES AGENCIES (HMA) Making a difference over the next 5 years: key themes to emerge. - Safeguarding public and animal health. - Supporting innovation. - Further improve the operational efficiency of medicines authorisation by MRP/DCP.
  7. 7. Slide 7 IMB INTERNATIONAL PROFILE EUROPE Provides significant resources to the European network Chair of the Board of the EMA Active participant in many EMA working groups Participant in the Heads of Medicines Agencies (HMA) (provides secretariat resource to the network) Active participant in HMA working groups including the CMDh, CMDv, WGEO
  8. 8. Slide 8 IMB INTERNATIONAL PROFILE EUROPE (contd.)  Joint Chair of the steering group on the European Benchmarking of Medicines Agencies (BEMA)  Member of the European Pharmacopoeia Commission (Chair 2004-2007)  Active participant in the Council of Europe Group of Specialists on Pharmaceutical Counterfeit Products (PC-ISP). Provided significant proposals in respect of the convention on counterfeit medical products.  Active participant in the Official Medicines Control Laboratories (OMCL) network
  9. 9. Slide 9 IMB INTERNATIONAL PROFILE OUTSIDE EUROPE Exchange Agreements signed with a number of international agencies Participant in International Conference on Harmonisation (ICH) Participation in shared inspection plans co- ordinated through the EMA Participation in and host (2007) to the International Summit of Heads of Medicines Agencies
  10. 10. Slide 10 INTERNATIONAL SUMMIT Some topics  Cooperation on inspections with EMA, FDA, TGA and some EU MS  Global manufacturing  Clinical trials in developing countries  Co-operation against counterfeits  Engagement on HTA  Regulatory Science  Herbal medicines
  11. 11. Slide 11 INTERNATIONAL REGULATORY COOPERATION STRATEGY Specifically IMB will endeavour:  To support initiatives that enhance public health protection in the products regulated  To support the international business based in Ireland and provide quality assurance externally in relation to all product leaving Ireland  To be an active participant in the European regulatory network and be in a position to influence European policy.  To support and participate in the development and delivery of international policy. Areas of particular focus at present include: - Anti-counterfeiting - Common standards for inspection - Maximising use of available resources, particularly for inspection - International network of shared information particularly in safety data
  12. 12. Slide 12 THE IMB – WORLD CLASS?  Management  Strategic planning  Vision and values  Restructuring – Process based and linked to technologies  Funding and funding model  Staffing – Development and knowledge network  Outreach – including HTA  Timelines  Clinical trials  Benchmarking – BEMA (Organisation, Assessment, Vigilance, Inspections) Fees 2011 - 20% reduction to type II variations - 10% reduction to type IB variations - 10% reduction to annual maintenance fees - 50% reduction to enforcement fees - 50% reduction to Article 61(3) fees
  13. 13. Slide 13 The contribution of a world-class regulatory environment to the future of the industry in Ireland Thank you! Pat O’Mahony Chief Executive, Irish Medicines Board Chairman, European Medicines Agency

×